160 related articles for article (PubMed ID: 1478342)
1. Validation of virus removal in large scale purification processes.
Fritsch E
Dev Biol Stand; 1992; 76():239-48. PubMed ID: 1478342
[No Abstract] [Full Text] [Related]
2. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
3. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
Celis P; Silvester G
Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
[TBL] [Abstract][Full Text] [Related]
4. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
[No Abstract] [Full Text] [Related]
5. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
Vicari G
Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
[TBL] [Abstract][Full Text] [Related]
6. Viral safety of biological products and the concept of validation.
Horaud F
Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
[No Abstract] [Full Text] [Related]
7. Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics.
Strauss DM; Lute S; Tebaykina Z; Frey DD; Ho C; Blank GS; Brorson K; Chen Q; Yang B
Biotechnol Bioeng; 2009 Oct; 104(2):371-80. PubMed ID: 19575414
[TBL] [Abstract][Full Text] [Related]
8. Validation of removal of human retroviruses.
Marcus-Sekura CJ
Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
[TBL] [Abstract][Full Text] [Related]
9. Criteria for the choice of viruses in validation studies.
Minor PD
Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805
[TBL] [Abstract][Full Text] [Related]
10. Philosophy and goals of validation for biotech products and the relevance of scale.
Hageman TC
Dev Biol Stand; 1992; 76():231-7. PubMed ID: 1478341
[TBL] [Abstract][Full Text] [Related]
11. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
[No Abstract] [Full Text] [Related]
12. Use of a statistical strategy to evaluate sources of variability in viral safety experiments for a recombinant biopharmaceutical.
McAllister PR; Shadle PJ; Smith TM; Scott RG; Lubiniecki AS
Dev Biol Stand; 1996; 88():111-21. PubMed ID: 9119122
[No Abstract] [Full Text] [Related]
13. Relationship between nature and source of risk and process validation.
Berthold W; Werz W; Walter JK
Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
[No Abstract] [Full Text] [Related]
14. Process evaluation for biopharmaceuticals: what is appropriate in process evaluation?
Lubiniecki AS; McAllister PR; Smith TM; Shadle PJ
Dev Biol Stand; 1996; 88():309-15. PubMed ID: 9119154
[No Abstract] [Full Text] [Related]
15. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of anti-viral filters.
Hughes B; Bradburne A; Sheppard A; Young D
Dev Biol Stand; 1996; 88():91-8. PubMed ID: 9119168
[TBL] [Abstract][Full Text] [Related]
17. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
18. Introduction to the issues: new potential contaminants and other exogenous agents.
Albrecht P
Dev Biol Stand; 1992; 76():255-8. PubMed ID: 1478344
[No Abstract] [Full Text] [Related]
19. Theoretical considerations on viral inactivation or elimination.
Willkommen H; Löwer J
Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
[No Abstract] [Full Text] [Related]
20. Changes to biological source materials.
Sewerin K; Shacter E; Robertson J; Wallerius C
Biologicals; 2006 Mar; 34(1):71-2. PubMed ID: 16480893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
